Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study

@article{Ichikawa2005TherapeuticEO,
  title={Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study},
  author={Yoichi Ichikawa and Terunobu Saito and Hisashi Yamanaka and Masashi Akizuki and Hirobumi Kondo and Shigeto Kobayashi and Hisaji Oshima and Shinichi Kawai and Nobuaki Hama and Hidehiro Yamada and Tsuneyo Mimori and Koichi Amano and Yasushi Tanaka and Yasuo Matsuoka and Sumiki Yamamoto and Tsukasa Matsubara and Norikazu Murata and Tomiaki Asai and Yasuo Suzuki and Japanese Ministry of Health Labour and Welfare's “ MTX–BUC Combination Study Group},
  journal={Modern Rheumatology},
  year={2005},
  volume={15},
  pages={323-328}
}
Disease-modifying antirheumatic drug (DMARD) combination therapies are used widely, but there have been few reports clearly demonstrating that combination therapy is more effective than DMARD monotherapy. We conducted a multicenter, double-blind controlled trial in order to clarify that the combination of methotrexate and bucillamine is more effective than either alone. The subjects of this study were 71 patients with active rheumatoid arthritis within 2 years of onset. Dosages were 8 mg… Expand
Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA
Abstract Bucillamine (Buc) is a disease-modifying antirheumatic drug (DMARD) developed in Japan, which has been used as one of the first-line DMARDs for the treatment of rheumatoid arthritis (RA) inExpand
Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA
TLDR
Responses to Buc treatment were better in males, patients with shorter duration of illness, and those who were rheumatoid factor-negative, and data support Buc as a candidate for being a first-line drug for the treatment of patients with RA. Expand
The usefulness of a new triple combination treatment utilizing methotrexate, salazosulfapyridine, and bucillamine in rheumatoid arthritis
TLDR
The triple DMARD combination therapy provided a new treatment option for those patients for whom treatment with biologics is difficult, and there was no significant difference in the degree of bone destruction between the two groups at 12 months. Expand
Efficacy and safety of bucillamine, a d-penicillamine analogue, in patients with active rheumatoid arthritis
Abstract Japanese rheumatologists consider bucillamine (Buc) to be a useful disease-modifying antirheumatic drug (DMARD) and often give Buc to patients with rheumatoid arthritis (RA) prior toExpand
Efficacy and safety of bucillamine, a d-penicillamine analogue, in patients with active rheumatoid arthritis
TLDR
The results suggested that Buc should be given to patients with moderately active RA either before or after the administration of MTX because its efficacy can be judged within 3 months and because serious adverse events are rare. Expand
Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial
TLDR
The study results suggest that iguratimod in combination with MTX was efficacious and had a manageable safety profile and was effective in Japanese patients with active rheumatoid arthritis. Expand
Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial
TLDR
The study results suggest that iguratimod in combination with MTX was efficacious and had a manageable safety profile and was effective in Japanese patients with active rheumatoid arthritis. Expand
Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial
Abstract Objectives To investigate the efficacy and safety of iguratimod (T-614) in Japanese patients with active rheumatoid arthritis who had inadequate response to stable background methotrexateExpand
A multicentre trial of bucillamine in the treatment of early rheumatoid arthritis (SNOW study)
Abstract In this study, we enrolled early rheumatoid arthritis (RA) patients at multiple institutes who fulfilled the American Rheumatism Association 1987 revised criteria for the classification ofExpand
A multicentre trial of bucillamine in the treatment of early rheumatoid arthritis (SNOW study)
TLDR
From the efficacy and safety viewpoints alike, BUC was useful as first-choice treatment for early RA. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 29 REFERENCES
Combination treatment of rheumatoid arthritis using azathioprine and methotrexate: a 48 week controlled clinical trial.
TLDR
It is established that the combination of MTX and AZA in the dosages employed is not associated with more toxicity than treatment with single agents, but enhanced efficacy is not seen. Expand
Efficacy of additive DMARD therapy in patients with rheumatoid arthritis. Double blind controlled trial using bucillamine and placebo with maintenance doses of gold sodium thiomalate.
TLDR
The usefulness of ADT was suggested by this trial; however, further confirmation by additional studies is still needed. Expand
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
TLDR
The combination of etanercept and methotrexate was significantly better in reduction of disease activity, improvement of functional disability, and retardation of radiographic progression compared with methotRexate or etanorcept alone. Expand
Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial.
TLDR
There were no significant differences in efficacy between combination and single therapy, only a modest trend favouring COMBI. Expand
Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial.
TLDR
Both combination therapy and MTX alone were superior to therapy with AZA alone for active RA but were not statistically different in their effect on outcome assessment. Expand
Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components
TLDR
This study suggests that an early initiation therapy of disease modifying drug seems to be of benefit, however, this study was unable to demonstrate a clinically relevant superiority of the combination therapy although several outcomes were in favour of this observation. Expand
Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group.
TLDR
Clinical responses following administration of leflunomide, a new therapeutic agent for the treatment of RA, were statistically superior to those with placebo and equivalent to Those with methotrexate treatment. Expand
Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.
TLDR
The triple combination of MTX, SSZ, and HCQ is well-tolerated, and its efficacy is superior to that of the double combination ofMTX and SSZ and is marginally superior toThat of thedouble combination ofmtX andHCQ. Expand
Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.
TLDR
In patients with rheumatoid arthritis, combination therapy with methotrexate, sulfasalazine, and hydroxychloroquine is more effective than either methot Rexate alone or a combination of sulfas alazine,and hydroxy chloroquine. Expand
Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group.
TLDR
In a six-month study, patients with severe rheumatoid arthritis and only partial responses to methotrexate had clinically important improvement after combination therapy with cyclosporine and metotrexate. Expand
...
1
2
3
...